Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 10Terminated 5Active not recruiting 4Recruiting 2Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 35Breast 11Gynecologic 3Genitourinary 3Dermatologic 3Head & Neck 2Tumor-Agnostic 1Thoracic 1Sarcoma 1NET 1Lymphoid 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 40Cisplatin 37Pemetrexed 33Radiotherapy 23Paclitaxel 22pembrolizumab 20durvalumab 19Docetaxel 19Gemcitabine 18Nivolumab 15Radiosurgery 14Etoposide 13atezolizumab 11Erlotinib Hydrochloride 11Taxes 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Bevacizumab 8Cyclophosphamide 7Platinum 6Gefitinib 6Surveys and Questionnaires 5Biopsy 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5sotorasib 4Ramucirumab 4Radiation 4Immunotherapy 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Capecitabine × Thoracic × Clear all
NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡